(CercleFinance.com) – BeiGene reported on Tuesday the positive results of a phase 3 clinical trial on tislelizumab, a drug whose distribution could be ensured by Novartis, in the treatment of liver cancer.
Based on these findings, tislelizumab met its primary endpoint of not being inferior to Bayer’s sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (HCC).
In its press release, BeiGene specifies that the study included more than 600 patients in the United States, Europe and Asia.
As a reminder, BeiGene and Novartis had entered into a collaboration agreement in early 2021 for the joint development, manufacture and marketing of tislelizumab, an anti-PD-1 antibody, in North America, Europe and Japan.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
